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Abstract. In acute promyelocytic leukemia (APL), 
rare and shows special clinical and biological features. It is estimated that about 3
patients will suffer extramedullary relapse. The most common site of EMD in APL is the
nervous system (CNS). At present, there are still many issues of EMD in APL needing further 
clarification, including pathogenesis, risk factors, prognosis and treatment. A better understanding 
of the biological mechanisms underlying EMD is important to be able to devise more 
prophylaxis and induction-consolidation therapeutic strategies
Introduction. Acute leukemia may present in a variety 
of extramedullary tissues with or without bone marrow 
disease.  Extramedullary  involvement  by  acute 
leukemia is a relatively rare but clinically significant 
phenomenon  that  often  poses  diagnostic  and 
therapeutic dilemmas. Myeloid sarcoma and leukemia 
cutis  are  two  well-known  EM  manifestations.  
Extramedullary disease (EMD) in acute promyelocytic 
leukemia (APL) is particularly rare and shows special 
clinical and biological features.
How common is  EMD in APL? The combination of 
all-trans retinoic acid (ATRA) and anthracyclin
chemotherapy,  together  with  maintenance  treatment, 
has  improved  the  outcome  of  APL.  In  fact, 
approximately 90% of patients with newly diagnosed 
APL  achieve  complete  remission  (CR).
estimated that 70–80% of these patients will remain in
remission.
1,3 However,  approximately  20
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In acute promyelocytic leukemia (APL), extramedullary disease (EMD) is particularly 
rare and shows special clinical and biological features. It is estimated that about 3
patients will suffer extramedullary relapse. The most common site of EMD in APL is the
. At present, there are still many issues of EMD in APL needing further 
clarification, including pathogenesis, risk factors, prognosis and treatment. A better understanding 
of the biological mechanisms underlying EMD is important to be able to devise more 
consolidation therapeutic strategies.
Acute leukemia may present in a variety 
tissues with or without bone marrow 
disease.  Extramedullary  involvement  by  acute 
leukemia is a relatively rare but clinically significant 
phenomenon  that  often  poses  diagnostic  and 
therapeutic dilemmas. Myeloid sarcoma and leukemia 
n  EM  manifestations.  
Extramedullary disease (EMD) in acute promyelocytic 
leukemia (APL) is particularly rare and shows special 
The combination of 
trans retinoic acid (ATRA) and anthracycline-based 
chemotherapy,  together  with  maintenance  treatment, 
has  improved  the  outcome  of  APL.  In  fact, 
approximately 90% of patients with newly diagnosed 
APL  achieve  complete  remission  (CR).
1-2 and  it  is 
80% of these patients will remain in
However,  approximately  20– 30%  of 
patients  will  eventually  relapse.
complication in APL: it is estimated that about 3
of  patients  will  suffer  extramedullary  relapse.
However,  since  the  introduction  of  ATRA  in  the 
treatment of patients with APL, EMD disease has been 
increasingly  reported;  in  fact,  in  the  literature  fewer 
than  25  well-documented  cases  had  been  described 
before  1995.
7 This  is  most  likely  in  part  due  to  the 
following reasons: 
a) APL patients may develop EMD 
because they are achieving longer survival times 
thanks to improved treatment regimens
b)  It  is  possible  that  the  drugs  employed  in  the 
induction  regimens  (ATRA,  anthracycline  and 
arsenic  trioxide)  do  not  reach  therapeutic 
concentrations  at  the  anatomical  sites  where 
EMD eventually develops
c)  It  is  also  possible  that  ATRA  therapy  might 
contribute  to  extramedullary  relapses  by 
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extramedullary disease (EMD) is particularly 
rare and shows special clinical and biological features. It is estimated that about 3–5% of APL 
patients will suffer extramedullary relapse. The most common site of EMD in APL is the central 
. At present, there are still many issues of EMD in APL needing further 
clarification, including pathogenesis, risk factors, prognosis and treatment. A better understanding 
of the biological mechanisms underlying EMD is important to be able to devise more effective CNS 
patients  will  eventually  relapse.
2 EMD  is  a  rare 
complication in APL: it is estimated that about 3–5% 
of  patients  will  suffer  extramedullary  relapse.
4-6
However,  since  the  introduction  of  ATRA  in  the 
nt of patients with APL, EMD disease has been 
increasingly  reported;  in  fact,  in  the  literature  fewer 
documented  cases  had  been  described 
This  is  most  likely  in  part  due  to  the 
a) APL patients may develop EMD more frequently 
because they are achieving longer survival times 
thanks to improved treatment regimens.
t  is  possible  that  the  drugs  employed  in  the 
induction  regimens  (ATRA,  anthracycline  and 
arsenic  trioxide)  do  not  reach  therapeutic 
at  the  anatomical  sites  where 
EMD eventually develops.
t  is  also  possible  that  ATRA  therapy  might 
contribute  to  extramedullary  relapses  by Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
modulating  and  upregulating  the  expression  of 
adhesion molecules on leukemic cells. 
EMD    commonly  occurs  within 1  year  of  achieving 
CR, but it can appear at any time during the disease 
course  and  can  be  isolated  or  can  precede  systemic 
relapse.
2,6 As to  cases of EMD at  APL presentation, 
although a few anecdotal reports have been made this 
observation is very uncommon.
8
What  are  the  most  frequent  anatomical  sites  of 
EMD in APL? The most frequent site of EMD in APL 
patients  is  the  central  nervous  system  (CNS)  and  at 
least 10% of hematologic relapses are accompanied by 
CNS involvement.
9 CNS relapse appears in around 1% 
of APL patients and may occur despite hematological 
remission.
6,10-12 The skin is the second most common 
site  of  EMD.
2 The  increased  frequency  of  EMD 
especially  in  these  two  sites  could  be  explained  by 
some biological effects of ATRA induction treatment.
In fact,  ATRA-driven differentiation of APL cells is 
associated  with  a  significant  upregulation  of  cellular 
adhesion molecules expressed on the cell surface, like 
LFA-1 and  VLA-4.
13 The  mechanism  of  APL blasts 
adhesion to the endothelium may be further increased 
by interleukin-1, via an effect which may be mediated 
through  an  increased  expression  of  ICAM-1  and 
VCAM-1  on  the  endothelial  cell  surface.
14 These 
surface proteins have both been demonstrated on the 
CNS  endothelium  and  have  been  implicated  in  the 
migration  processes  of  leukocytes  across  the  blood–
brain barrier (BBB), through interactions with LFA-1 
and VLA-4, respectively.
9 Since both LFA-1 and VLA-
4 are upregulated in APL blasts treated with retinoids, 
it  is  reasonable  to  suppose  that  the  upregulation  of 
these adhesion molecules may promote passage across 
the BBB of ATRA-treated APL cells, thereby creating 
the conditions for a subsequent CNS relapse (Figure 
1). Moreover, ATRA also stimulates keratinocytes to 
proliferate and upregulate their expression of ICAMs.
9
It has been suggested that the migration of leukemic 
cells  into  the  skin  and  other  tissues  during  ATRA 
induction  treatment  may  leave  a  reservoir  of  viable 
leukemic  cells  in  these  sites,  that  eventually  may 
proliferate  and  cause  EMD.  These  biological  events 
could  account  for  the  clinical  observation  of  a 
preferential  skin  localization  of  APL  cells  relapsing 
after ATRA treatment. Moreover, a high frequency of 
EMD  in  APL  may  also  be  related  to  the  ATRA-
induced upregulation of G-CSF receptors in APL cells, 
making  them  more  sensitive  to  endogenous  or 
exogenous  G-CSF  effects.
15 Other  described  sites  of 
EMD  in  APL  include:  the  testes,  sites  of  vascular 
access, external ear and auditory canal, lung, pleura, 
heart,  lymph  nodes,  mediastinum,  thymus,  spine, 
breast, pelvis, mandible and gingiva, bowel. Since in 
patients  affected  by  ATRA  syndrome  APL  cells 
infiltrate  multiple  tissues  and  organs,  it  has  been 
hypothesized that ATRA could promote the migration 
of  differentiating  blasts  into  several  tissues, 
constituting a reservoir of viable leukemic cells. These 
cells  could  later  proliferate  and  result  in  an 
extramedullary recurrence.
16-17 However, the issue as to 
whether ATRA promotes EMD in APL is still highly 
controversial,  since  several  studies  have  reached 
different conclusions.
5-7,18-19
Are there risk factors for an EMD onset in APL?
Several factors have been associated with a higher risk 
of  extramedullary  relapse  such  as  younger  age  (<45 
years), a high WBC count at diagnosis, microgranular 
morphology, expression of CD2 and/or CD56, PML-
RAR bcr3  isoform  expression,  ATRA  syndrome, 
monotherapy  regimens,  and  the  use  of  therapy 
schedules  that exclude cytarabine.
2,4,12,20-21 Moreover, 
two  recent  studies
4,22 reported  a  significantly  higher 
incidence  of  CNS  involvement  in  patients  with  an 
initial  WBC  of  more  than  10  x10
9/L.  In addition  to 
hyperleukocytosis,  the  PETHEMA  study  also 
identified  a  previous  CNS  hemorrhage  during 
induction  as  an  independent  risk  factor  for  CNS 
relapse.
22 It  has  recently  been  demonstrated  that 
CD56+  APL  has  a  greater  risk  of  extramedullary 
relapse.
21 The  higher  frequency  of  coexpression of 
stem cell (CD117) and NK-cell antigens (CD2, CD7) 
in  CD56+ APL cells  suggests that  in  some  of  these 
cases APL might have arisen in progenitors that did not 
undergo lineage restriction.
23 Therefore, it is possible 
that CD56+ APL may emerge from a more immature, 
undifferentiated and pluripotent leukemic stem cell that 
is  less  sensitive  to  the  combination  of  ATRA  and 
anthracyclines. This could explain the higher frequency 
of extramedullary relapse in these cases.
21,24-25
What is the prognosis of EMD in APL? Which is 
the best therapy? Because of the rarity of the disease, 
the  prognosis  of  patients  with  EMD  in  APL  is  still 
unclear.    The  GIMEMA  study
6 reported  that  the 
outcome  was  similar  to  that  of  patients  who 
experienced isolated bone marrow relapse, whereas in 
the  joint study by the  PETHEMA  and the  European 
APL  groups
4 it  was  found    that  patients  with  an 
extramedullary  relapse  had  a  poorer  outcome.  EMD 
can occur in isolation or associated with bone marrow 
involvement  as  a  first  relapse,  but  also  after  one  or 
more hematologic relapses. The molecular status in the 
peripheral blood/bone marrow did not seem to predict 
the  possibility  of  EMD  relapse.
5-6 Management  of 
relapse in the CNS and other extramedullary sites in 
APL patients is a challenging issue on which there is a 
strong need for further data.  The optimal management Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. ATRA-driven differentiation of APL cells is associated with the upregulation of cellular adhesion molecules like LFA-1 and VLA-
4. The mechanism of APL blasts adhesion to the endothelium may be further increased by interleukin-1, an effect which may be mediated 
via an increased expression of ICAM-1 and VCAM-1 on the CNS endothelium. Since both LFA-1 and VLA-4 are upregulated in APL blasts 
treated with retinoids, it is reasonable to suppose that the upregulation of these adhesion molecules might promote passage across the BBB of 
ATRA-treated APL cells, thereby creating the conditions for a subsequent CNS relapse. Moreover, CD56 expression on APL cells  may also 
foster CNS relapse.
of  APL  patients  in  different  situations  has  not  been 
critically  assessed.
26 Because  the  majority  of  CNS 
relapses  occurs  in APL  patients  with 
hyperleukocytosis,
4 CNS  prophylaxis  for  patients  in 
this particular high-risk setting may be appropriate.
26 In 
these cases CNS prophylaxis should be performed after 
the  achievement  of  CR  because  lumbar  puncture  at 
presentation  and  during induction  is  extremely 
hazardous. However, the benefit of this kind of strategy 
has not yet been clearly established.
The  role  of  ATRA  and  arsenic  trioxide  in  the 
therapeutic management of CNS relapse is still unclear 
because it is not known whether these drugs cross the 
BBB;  nevertheless,  some  authors  have  reported 
responses to  these agents in  patients with  meningeal 
disease.
27-28 This may be due to the EMD disrupting the 
BBB. Arsenic trioxide has also been reported to cross 
the BBB and may be useful as a therapeutic agent to 
control CNS relapse.
29 On the other hand, some reports 
have confirmed that although arsenic crosses the BBB
when administered intravenously, the concentration in 
CSF  is  probably  not  sufficient  to  treat  meningeal 
leukemia.
30-31 Recently, as induction treatment of CNS 
relapse,  the  European  LeukemiaNet 
recommendations
26 proposed  a  schedule  of  weekly 
triple  intrathecal  therapy  (ITT)  with  methotrexate, 
hydrocortisone,  and  cytarabine  until  complete 
clearance  of  blasts  in  the  cerebrospinal  fluid  (CSF), 
followed by 6 to 10 more spaced-out ITT treatments as 
consolidation. In these cases systemic treatment should 
also be given because CNS disease is almost invariably 
associated with hematologic or molecular relapse in the 
marrow.  Chemotherapy  regimens  with  high  CNS 
penetrance,  such  as  high-dose  cytarabine,  have  been 
used  in  this  situation.  In  patients  responding  to 
treatment, allogeneic or autologous transplant is then 
recommended as consolidation treatment, together with 
craniospinal  irradiation.  It  was  demonstrated  that 
cytarabine during consolidation treatment significantly 
reduced the relapse rate in high-risk APL patients.
32-33
Because  of  the  limited  numbers  of  EMD  events 
reported in these studies, it is very hard to draw firm 
conclusions regarding the best schedule of cytarabine 
to use in the consolidation regimen to prevent the EMD 
in APL. In cases of promyelocytic sarcoma, wherever 
it is localized, radiation and intensive systemic therapy 
might be considered. Recently, successful treatment of 
relapsed and refractory EMD with Tamibarotene,
34 a 
synthetic  retinoid  approved  in  Japan  for  use  in 
relapsed/refractory  APL,  has  been  reported.
35
Tamibarotene is 10 times more potent than ATRA as 
an  inducer  of  HL-60  and  NB-4  leukemia  cell  lines 
differentiation.  While  tamibarotene  has  displayed  a 
significant activity in bone marrow-relapsed APL, its Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
efficacy  in  EMD  needs  to  be  confirmed  in  further 
studies.
Conclusions. At  present,  there  are  still  many  open 
issues  on  EMD  in  APL  patients.  However,  some 
aspects  are  becoming  clearer.  An  improved 
understanding  of  the  biological  mechanisms  that 
underlie EMD should allow us to devise more effective 
prophylaxis and induction therapeutic strategies against 
this severe clinical presentation.
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